Sandra Isabelle Barros Alves - 31 Mar 2025 Form 3 Insider Report for Repare Therapeutics Inc. (RPTX)

Role: SVP, Finance and CAO
Signature: /s/ Steve Forte, Attorney-in-Fact
Issuer symbol: RPTX
Transactions as of: 31 Mar 2025
Net transactions value: $0
Form type: 3
Filing time: 29 Apr 2025, 17:05:52 UTC
Next filing: 29 Apr 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	RPTX	Common Shares						25,522	31 Mar 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	RPTX	Employee Stock Option (right to buy)							31 Mar 2025	Common Shares	57,736	$6.79	Direct	F2
holding	RPTX	Employee Stock Option (right to buy)							31 Mar 2025	Common Shares	21,565	$36.91	Direct	F2
holding	RPTX	Employee Stock Option (right to buy)							31 Mar 2025	Common Shares	38,645	$15.63	Direct	F3
holding	RPTX	Employee Stock Option (right to buy)							31 Mar 2025	Common Shares	18,600	$12.42	Direct	F4
holding	RPTX	Employee Stock Option (right to buy)							31 Mar 2025	Common Shares	14,300	$6.95	Direct	F5
holding	RPTX	Employee Stock Option (right to buy)							31 Mar 2025	Common Shares	26,000	$1.17	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	14,700 Common Shares represent restricted stock unit ("RSU") grants. 3,433 RSUs will vest on January 30, 2026; 4,767 RSUs will vest in two equal installments commencing on March 1, 2026; and 6,500 RSUs will vest in three equal installments commencing on March 4, 2026, subject to Reporting Person continuing to provide service through each such date.
F2	Fully vested and exerciseable.
F3	Twenty-five percent (25%) of the shares subject to the option vested on January 18, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or will vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.
F4	Twenty-five percent (25%) of the shares subject to the option vested on January 30, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or will vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.
F5	Twenty-five percent (25%) of the shares subject to the option vested on March 1, 2025, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or will vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.
F6	13,000 shares subject to the option will vest on March 4, 2026. With respect to the remaing 13,000 shares subject to the option, twenty-five percent (25%) will vest on March 4, 2026, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.